CrushSCI.com
120.6Average days
91.5Median days
30Fastest days
226Longest days
4532025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

89 days

Relationships among nitrous oxide exposure, neurological injury and biomarkers

Authors
Laxna Bhujel; Angela L. Chiew; Bhashita Jagarlamudi; Pramod Chandru; Naren Gunja; Nancy Briggs; Betty S. ChanShow moreShow less
Affiliations
1. Faculty of Medicine and Health, School of Clinical Medicine University of New South Wales Sydney New South Wales Australia; 2. Clinical Toxicology Unit and Emergency Department Prince of Wales Hospital Sydney New South Wales Australia; 3. Department of Clinical Pharmacology and Toxicology Therapeutics Centre St Vincent's Hospital Darlinghurst New South Wales Australia; 4. Department of Clinical Toxicology Westmead Hospital Westmead New South Wales Australia; 5. Emergency Department, Clinical Toxicology Unit Nepean Hospital Kingswood New South Wales Australia; 6. Faculty of Medicine and Health University of Sydney Sydney New South Wales Australia; 7. Stats Central, Mark Wainwright Analytical Centre University of New South Wales Sydney New South Wales AustraliaShow moreShow less
Official full-text evidence DOI Publisher page
94 days

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

Authors
Tanja Mueller; Christine Crearie; Liya Lu; Jiafeng Pan; Fraser N. Sneden; David Martin; Amanj Kurdi; Catherine S. Thomson; Julie Clarke; Marion BennieShow moreShow less
Affiliations
1. Strathclyde Institute of Pharmacy and Biomedical Sciences University of Strathclyde Glasgow UK; 2. Public Health Scotland Glasgow/Edinburgh UK; 3. NHS Greater Glasgow and Clyde Glasgow UKShow moreShow less
Official full-text evidence DOI Publisher page
226 days

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

Authors
Zubida M. Al‐Majdoub; Armin Sepp; Amin Rostami‐Hodjegan; Brahim AchourShow moreShow less
Affiliations
1. Centre for Applied Pharmacokinetic Research, School of Health Sciences University of Manchester Manchester UK; 2. Certara Predictive Technologies Certara UK Sheffield UK; 3. Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy the University of Rhode Island Kingston Rhode Island USAShow moreShow less
Official full-text evidence DOI Publisher page
30 days

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

Authors
Tianshu Gu; Yang Chen; Nan Zhang; Uazman Alam; Riccardo Proietti; Tong Liu; Kang‐Yin Chen; Gregory Y. H. LipShow moreShow less
Affiliations
1. Liverpool Centre for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart and Chest Hospital Liverpool UK; 2. Tianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology The Second Hospital of Tianjin Medical University Tianjin China; 3. Department of Cardiovascular and Metabolic Medicine University of Liverpool Liverpool UK; 4. Liverpool Centre for Cardiovascular Sciences University of Liverpool and Liverpool University Hospitals NHS Foundation Trust Liverpool UK; 5. Centre for Biomechanics and Rehabilitation Technologies Staffordshire University Stoke‐on‐Trent UK; 6. Department of Clinical Medicine Aalborg University Aalborg Denmark; 7. Department of Cardiology, Lipidology and Internal Medicine with Intensive Coronary Care Unit Medical University of Bialystok Bialystok PolandShow moreShow less
Official full-text evidence DOI Publisher page
172 days

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

Authors
Anna Lundahl; Jonathan Grigg; Lubna Abuqayyas; Piotr Kuna; Gillian Hunter; Beata Pawlikowska; Jacob Leander; Michael Levin; Atul Gupta; James Paton; Katharine C. Pike; Jane R. Parnes; Gun Almqvist; Stephanie L. Roseti; the study investigatorsShow moreShow less
Affiliations
1. Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca Gothenburg Sweden; 2. Centre for Genomics and Child Health, Blizard Institute Queen Mary University of London London UK; 3. Clinical Pharmacology, Modeling and Simulation Amgen Cambridge Massachusetts USA; 4. Department of Internal Medicine, Asthma and Allergy Medical University of Łódź Łódź Poland; 5. Biometrics, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Cambridge UK; 6. Biometrics, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Warsaw Poland; 7. Division of Paediatric Allergology University of Cape Town Cape Town South Africa; 8. Department of Paediatric Respiratory Medicine King's College Hospital London UK; 9. Faculty of Life Sciences and Medicine King's College London London UK; 10. School of Medicine, College of Medical, Veterinary & Life Sciences University of Glasgow Glasgow UK; 11. Department of Paediatric Respiratory Medicine Bristol Royal Hospital for Children Bristol UK; 12. Early Development Amgen Thousand Oaks California USA; 13. Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden; 14. Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Gaithersburg Maryland USAShow moreShow less
Official full-text evidence DOI Publisher page
222 days

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus

Authors
Nele Goeyvaerts; Per Olsson Gisleskog; Martine Neyens; Juan José Perez Ruixo; Saberi Rana Ali; Iolanda Cirillo; Oliver AckaertShow moreShow less
Affiliations
1. Johnson & Johnson Beerse Belgium; 2. POG Pharmacometrics London UK; 3. Johnson & Johnson Madrid Spain; 4. Johnson & Johnson Titusville New Jersey USA; 5. Johnson & Johnson Raritan New Jersey USAShow moreShow less
Official full-text evidence DOI Publisher page

FAQ

How long does BRITISH JOURNAL OF CLINICAL PHARMACOLOGY take to review a manuscript?

As of 2026-11-17, CrushSCI has 10 complete review records for BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. The fastest paper went from submission to acceptance in 30 days (Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study, received 2026-05-26, accepted 2026-06-25); the slowest took 226 days. The average is 120.6 days and the median is 91.5 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.